Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Credo Technology Group Holding Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Credo Technology Group Holding Ltd trades at $254.49 (market cap $44.74B). The key difference: Credo Technology Group Holding Ltd is far larger — about 4.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| BIO | CRDO | |
|---|---|---|
Market Cap | $9.39B | $44.74B |
Sector | Health | Technology |
52-Week High | $356.25 | $302.52 |
52-Week Low | $241.71 | $87.81 |
Enterprise Value | $9.14B | $43.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
CRDO trades at $249.89, up 8.45% today, with strong technical momentum above key support at $237. The stock shows exceptional fundamental growth with revenue surging from $437M in 2025 to $1.3B projected for 2026, while maintaining robust 35.37% net margins. Recent news highlights Credo's strategic positioning in AI infrastructure through contributions to the Open Compute Project and institutional accumulation.
Outlook remains positive given accelerating AI capex and strong analyst consensus (86.7% buy ratings) with $285.42 price target. Key risks include premium valuation (P/E 95.6), customer concentration, and execution challenges in scaling operations amid competitive AI infrastructure landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
